By Eric Sorensen, WSU science writer SEATTLE – A neurodegenerative disease drug developed at Washington State University will likely qualify for a federal “fast-track” designation and go into clinical trials next year, said Leen Kawas, CEO of M3 Biotechnology Inc.
SEATTLE – Activating or inhibiting the growth factors linked to dementia, cancer and wound healing will be discussed at the free, public Washington State University Innovators lecture and reception 4-6 p.m. Thursday, April 9, at the Bell Harbor International Conference Center, 2211 Alaskan Way, Pier 66, Seattle.
PULLMAN – Volunteers are needed for a new study of memory loss that is getting under way at WSU. The researchers hope to enroll 100 volunteers who are not experiencing memory problems, 50 who are experiencing mild memory problems, and 50 who have been diagnosed with a progressive memory disorder such as Alzheimer’s disease. Participants […]
A black canvas notebook and a timer are the low-tech tools Eleanor Catlin is using to keep her independence.For the past year, she has been keeping track of her life hour by hour throughout the day. On the right page is her plan, where she writes down any appointments or errands she needs to do, […]